Literature DB >> 1403341

Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid treated cystic fibrosis patients.

J W Smith1, J L Colombo, T L McDonald.   

Abstract

Serum amyloid A (SAA) and C-reactive protein (CRP) levels were compared in 830 serum samples from 155 cystic fibrosis (CF) patients. Correlation coefficients were calculated for all samples (r = 0.73), for samples from non-corticosteroid treated (CFNS) patients (n = 698, r = 0.80), and for samples from corticosteroid treated (CFS) patients (n = 132, r = 0.35). SAA was the more sensitive indicator of pulmonary inflammation when SAA and CRP were compared to pulmonary function tests of 49 hospitalized patients at admission and discharge. CRP levels were significantly (p less than .05) lower at admission in CFS patients than in CFNS patients, whereas SAA levels were not significantly different between the two groups. All nine CFS patients hospitalized had elevated SAA levels (average 22 times above normal limits) at admission, while only six had elevated CRP levels (average 3.7 times above normal limits) at admission. In the 40 CFNS patients both SAA and CRP levels were significantly elevated at admission. In each case SAA and CRP levels declined as pulmonary functions improved with effective antimicrobial therapy. In three instances SAA levels increased during hospitalization while CRP levels did not. In each case, rising SAA levels indicated clinical deterioration associated with evolving resistance of P. aeruginosa which required a change in antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1403341     DOI: 10.1002/jcla.1860060410

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  9 in total

1.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

Authors:  Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

2.  Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis.

Authors:  T Yamada; Y Okuda; K Takasugi; K Itoh; J Igari
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

3.  Comparison of serum amyloid A and C-reactive protein as diagnostic markers of systemic inflammation in dogs.

Authors:  Michelle B Christensen; Rebecca Langhorn; Amelia Goddard; Eva B Andreasen; Elena Moldal; Asta Tvarijonaviciute; Jolle Kirpensteijn; Sabrina Jakobsen; Frida Persson; Mads Kjelgaard-Hansen
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

4.  Systemic serum amyloid A as a biomarker for exposure to zinc and/or copper-containing metal fumes.

Authors:  R Baumann; M Gube; A Markert; S Davatgarbenam; V Kossack; B Gerhards; T Kraus; P Brand
Journal:  J Expo Sci Environ Epidemiol       Date:  2017-02-08       Impact factor: 5.563

5.  Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase.

Authors:  Vihas T Vasu; Sharon J de Cruz; Jessica S Houghton; Keri A Hayakawa; Brian M Morrissey; Carroll E Cross; Jason P Eiserich
Journal:  Free Radic Res       Date:  2010-10-18

6.  Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone.

Authors:  J W Smith; T L McDonald
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

7.  Procalcitonin predicts the severity of cystic fibrosis pulmonary exacerbations and readmissions in adult patients: a prospective cohort study.

Authors:  Kristina L Bailey; Peter J Murphy; Olena K Lineberry; Matthew R Haack; John D Dickinson; Andre C Kalil
Journal:  J Investig Med       Date:  2020-01-21       Impact factor: 2.895

8.  The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial.

Authors:  M S Jurgens; M Safy-Khan; M J H de Hair; J W J Bijlsma; P M J Welsing; J Tekstra; F P J G Lafeber; E H Sasso; J W G Jacobs
Journal:  Arthritis Res Ther       Date:  2020-09-09       Impact factor: 5.156

9.  Cellular mechanisms involved in the pathogenesis of airway remodeling in chronic lung disease.

Authors:  E Arellano-Orden; C Calero Acuña; V Sánchez-López; C López Ramírez; R Otero-Candelera; C Marín-Hinojosa; Jl López Campos
Journal:  Eur Clin Respir J       Date:  2022-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.